Top Device Companies

Genzyme Reported A Buyout Target Of France’s Sanofi-Aventis

Genzyme reportedly has been approached by French drug maker Sanofi Aventis with an offer to buy the company. A source familiar with the matter said Genzyme was considering the offer even though it had expressed no interest in selling. Some analysts estimate Genzyme stockholders would ask for $70 to $80 a share. According to some sources, Genzyme, which makes medical devices in addition to biotech drugs, was approached by Sanofi-Aventis two weeks ago with an informal bid. (Click here for more)

“Genzyme Weighs Sanofi Approach: Source” – Reuters (7/26/10)

Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Available for purchase now!

Abbott, Medtronic, J&J Others Seek To Sell Both Insulin And Devices

Abbott Laboratories, Medtronic and other large makers of insulin-delivery devices seek to cross the line into selling the insulin used in them. In addition To Abbott and Medtronic, other large players are Roche Holding, Johnson & Johnson and now Sanofi-Aventis, a drug maker about to cross the line from the other direction. The combination is considered vertical integration, usually made through a partnership with a firm that makes the other side of the combination. J&J already has several partnerships to combine insulin and a delivery device. (Click here for more – a subscription may be required)

“Pondering A Vertically Integrated Insulin Machine” – Wall Street Journal (3/28/10)

Medical device manufacturers facing many challenges: from the rising clout of group purchasing organizations (GPOs) to payment bundling and physicians' growing allegiance with hospitals in product price negotiations. Get all the answers now in new Medtech Insight's new 24-page Special Report: Medical Device Landscape: How regulatory changes and cost control measures are reshaping the industry. Available for purchase now!

Deals Shaping the Medical Industry (03/2009)

Article preview from IN VIVO - March 2009

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.

The Cost-Sharing Solution: The New NICE Ticket

Article preview from IN VIVO - March 2009

J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.

Approval Delays for J&J/Basilea's Ceftobiprole Shake Partnership

Article preview from IN VIVO - March 2009

Basilea has become so frustrated with partner Johnson & Johnson's efforts--or lack thereof--to get anti-infective ceftobiprole past the regulators that it has resorted to arbitration. The biotech had few other options, but probably has most to lose.

Sanofi-Aventis Sees Medical Devices Leading Diversification Effort

Sanofi-Aventis of France is looking to medical devices to lead the diversification it expects to help drive its way to a global health care business. Sanofi's CEO says it is not after a big acquisition, as rumored. Instead, Chris Viehbacher said, Sanofi expects to focus on small- and mid-size deals in several areas instead of focusing on a single mega-merger. He said Sanofi prefers partnerships with other companies rather than just buying them out. Viehbacher said he would be looking at medical technology among other health care concerns in weighing further diversification. (Click here for more)

“Sanofi Eyes Vet, Medech But No Chasing BMS” – Reuters (3/5/09)

Get the week's top medical device news sent directly to you. Sign up for the FREE once-a-week email newsletter from Top Device Companies.com